Barisani-Asenbauer T
Laura Bassi Centre for Ocular Inflammation & Infection Center for Pathophysiology, Immunology & Infectiology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Wien, Österreich.
Ophthalmologe. 2011 Jan;108(1):21-4. doi: 10.1007/s00347-010-2257-x.
Biologics are increasingly being used in the treatment of non-infectious sight-threatening uveitis. While the advantages of biologics, such as avoidance of glucocorticoid side-effects or rapid control of intraocular inflammation therapy refractive to corticosteroids, cannot be dismissed the treating ophthalmologist should be aware of the specific risks. Biologics increase the risk for severe and atypical infections, lymphomas and other malignancies. Treatment should only be initiated when profound knowledge about indications, management and monitoring of treatment with biologics is readily available. Weighing up the risks versus the benefits should be made on an individual basis and guide patient consultation.
生物制剂越来越多地用于治疗非感染性威胁视力的葡萄膜炎。虽然生物制剂的优势,如避免糖皮质激素副作用或快速控制对皮质类固醇治疗无效的眼内炎症,不容忽视,但治疗眼科医生应了解其特定风险。生物制剂会增加严重和非典型感染、淋巴瘤及其他恶性肿瘤的风险。只有在对生物制剂治疗的适应症、管理和监测有深入了解时,才能开始治疗。应根据个体情况权衡风险与益处,并指导患者咨询。